Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) said unit Shanghai Fosun Pharmaceutical Industrial Development's drug registration application for Luvometinib Tablets was accepted by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.
The drug is indicated for the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis (LCH).
The application was included in the list of priority review.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments